Developer docs
API playgroundTry for free, no card

Search company profiles

Gi-Biome

Full company profile

uuid0022qw3

Namestring
Gi-Biome
Websiteurl
gi-biome.com
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

Gi-Biome is a South Korean biotechnology company founded in 2018 that conducts research and development on intestinal immune system and microbiome combination treatments, operating from Seongnam with limited publicly disclosed operational details.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
microbiome therapeutics, gut immunology research, combination therapy development, intestinal immune system, biotech R&D services
Industry4 codes
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Microbiome Therapeutics R&D
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gi-Biome is a for-profit biotechnology research and development company that focuses on the intestinal immune system and the microbiome, working on combination treatments that integrate these two domains. The company conducts R&D activities aimed at developing novel therapeutic approaches for gut-related health conditions. Founded in 2018 and headquartered in Seongnam, South Korea.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Intestinal Immune System and Microbiome Combination Treatment R&D
CategoryBiotechnology R&D Services
Description

Research and development services focused on combination treatments that integrate the intestinal immune system and the microbiome. The offering is targeted at pharmaceutical, biotech, and research partners seeking novel therapeutic approaches in gut health.

No data
Peers10 records
TypeBroad incumbent
Description

Rebiotix pioneered FDA-approved microbiome therapy RBX2660 (now Ferring's REBYOTA) for recurrent C. difficile. As a Ferring unit it is a broad-incumbent in live biotherapeutics with overlapping GI focus.

TypeEmerging player
Description

US-based microbiome company combining fungal and bacterial therapeutics research, reflecting the broader microbiome-immune R&D model Gi-Biome pursues, albeit at earlier translational maturity.

TypeDirect peer
Description

European clinical-stage microbiome therapeutics company with MaaT013 for GI graft-versus-host disease. Comparable as a focused microbiome-GI therapeutics developer.

TypeDirect peer
Description

Microbiome-derived drug developer focused on GI inflammation and immuno-oncology, with both small-molecule and microbial approaches relevant to Gi-Biome's combination-treatment concept.

54D pharma
TypeDirect peer
Description

UK-based microbiome therapeutics company developing single-strain and multi-strain live biotherapeutics across oncology, GI, and respiratory indications.

6Second Genome
TypeDirect peer
Description

Microbiome R&D company leveraging microbiome-immune science for therapeutic discovery, comparable to Gi-Biome on platform-driven microbiome-immune R&D.

TypeDirect peer
Description

Pioneer in microbiome therapeutics with SER-109 approved for recurrent C. difficile infection and additional GI programs. Operates in the same therapeutic area with overlapping mechanism ambitions.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined consortia of bacteria for GI and immune-mediated indications. Direct comparator to Gi-Biome on the microbiome-immune mechanism axis.

TypeEmerging player
Description

Clinical-stage company developing microbiome-based and antiviral therapies; emerging overlap with Gi-Biome through microbiome programs targeting GI and immune-related conditions.

TypeEmerging player
Description

France-based biotech developing microbiome-protective therapeutics to prevent antibiotic-induced dysbiosis and CDI. Relevant as a European emerging peer in microbiome-focused GI therapeutic development.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gi-Biome

Microbiome Therapeutics R&Dgi-biome.com

Gi-Biome is a South Korean biotechnology company founded in 2018 that conducts research and development on intestinal immune system and microbiome combination treatments, operating from Seongnam with limited publicly disclosed operational details.

Gi-Biome firmographics

Firmographics
Name
Gi-Biome
Website
https://gi-biome.com
Company type
Private
Founded year
2018
Headcount range
1–10 employees
Short description
Gi-Biome is a South Korean biotechnology company founded in 2018 that conducts research and development on intestinal immune system and microbiome combination treatments, operating from Seongnam with limited publicly disclosed operational details.
Ownership category
akta.pro rank

Gi-Biome industry classification

Industry
Product category
Microbiome Therapeutics R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)

Keywords

  • Microbiome therapeutics
  • Gut immunology research
  • Combination therapy development
  • Intestinal immune system
  • Biotech R&D services

Where Gi-Biome is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Markets served

Gi-Biome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Gi-Biome product offering

Product offering

Core offering

Gi-Biome is a for-profit biotechnology research and development company that focuses on the intestinal immune system and the microbiome, working on combination treatments that integrate these two domains. The company conducts R&D activities aimed at developing novel therapeutic approaches for gut-related health conditions. Founded in 2018 and headquartered in Seongnam, South Korea.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intestinal Immune System and Microbiome Combination Treatment R&D Research and development services focused on combination treatments that integrate the intestinal immune system and the microbiome. The offering is targeted at pharmaceutical, biotech, and research partners seeking novel therapeutic approaches in gut health.

Companies that use Gi-Biome

Customer profile

Ideal customer profiles1 record

Gi-Biome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gi-Biome competitors and assessment

Company assessment

Broad incumbents

  • Rebiotix (Ferring Pharmaceuticals): Rebiotix pioneered FDA-approved microbiome therapy RBX2660 (now Ferring's REBYOTA) for recurrent C. difficile. As a Ferring unit it is a broad-incumbent in live biotherapeutics with overlapping GI focus.

Emerging players

  • BIOHM Health: US-based microbiome company combining fungal and bacterial therapeutics research, reflecting the broader microbiome-immune R&D model Gi-Biome pursues, albeit at earlier translational maturity.
  • Assembly Biosciences: Clinical-stage company developing microbiome-based and antiviral therapies; emerging overlap with Gi-Biome through microbiome programs targeting GI and immune-related conditions.
  • Da Volterra: France-based biotech developing microbiome-protective therapeutics to prevent antibiotic-induced dysbiosis and CDI. Relevant as a European emerging peer in microbiome-focused GI therapeutic development.

Direct peers

  • MaaT Pharma: European clinical-stage microbiome therapeutics company with MaaT013 for GI graft-versus-host disease. Comparable as a focused microbiome-GI therapeutics developer.
  • Enterome: Microbiome-derived drug developer focused on GI inflammation and immuno-oncology, with both small-molecule and microbial approaches relevant to Gi-Biome's combination-treatment concept.
  • 4D pharma: UK-based microbiome therapeutics company developing single-strain and multi-strain live biotherapeutics across oncology, GI, and respiratory indications.
  • Second Genome: Microbiome R&D company leveraging microbiome-immune science for therapeutic discovery, comparable to Gi-Biome on platform-driven microbiome-immune R&D.
  • Seres Therapeutics: Pioneer in microbiome therapeutics with SER-109 approved for recurrent C. difficile infection and additional GI programs. Operates in the same therapeutic area with overlapping mechanism ambitions.
  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined consortia of bacteria for GI and immune-mediated indications. Direct comparator to Gi-Biome on the microbiome-immune mechanism axis.

Market position

Customer concentration

Gi-Biome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gi-Biome leadership team

Management profile

Number of profiles

Profiles1 record

Gi-Biome funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gi-Biome M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gi-Biome

What does Gi-Biome do?

Gi-Biome is a for-profit biotechnology research and development company that focuses on the intestinal immune system and the microbiome, working on combination treatments that integrate these two domains. The company conducts R&D activities aimed at developing novel therapeutic approaches for gut-related health conditions. Founded in 2018 and headquartered in Seongnam, South Korea.

When was Gi-Biome founded?

Gi-Biome was founded in 2018. It employs 1 to 10 people.

Where is Gi-Biome based?

Gi-Biome is headquartered in Seongnam, South Korea, in the Asia region.

Who are Gi-Biome's main competitors?

Rebiotix (Ferring Pharmaceuticals) is listed as a broad incumbent. Emerging players are BIOHM Health, Assembly Biosciences and Da Volterra. Direct peers are MaaT Pharma, Enterome, 4D pharma, Second Genome, Seres Therapeutics and Vedanta Biosciences.

Does Gi-Biome have an API?

No public API is recorded for Gi-Biome.

What industry is Gi-Biome in?

Gi-Biome's product category is Microbiome Therapeutics R&D. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling), with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales